1. Introduction {#s0005}
===============

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease affecting motor neurons, leading to death within approximately three years, usually due to respiratory failure ([@b0005]). Heritability studies suggest that genetic factors account for approximately 60% of the risk of developing ALS, while the remaining 40% is due to environmental exposures ([@b0010]). The possible impact of lifetime physical activity (PA) on the risk of developing ALS has been investigated, since vigorous physical exercise might cause oxidative stress and glutamate excitotoxicity ([@b0015], [@b0020]). Nevertheless, published studies about cumulative, leisure and occupational PA as a risk factor are inconclusive ([@b0025]). The reasons of such heterogeneity of results include differences in PA quantification and study design, the difficulty of evaluating a single environmental factor among the others, the variability of exposures in space and time, and possible gene-environment interactions. A detrimental role of sport practice on the risk of ALS has been hypothesized by studies on former athletes, including Italian professional soccer players ([@b0030]) and American football players ([@b0035]). A recent multicentre, cross-cultural, population-based, case-control study performed in the context of the Euro-MOTOR Project showed a linear association between lifetime PA and the risk of ALS, that was independent of age, sex, education, smoking and alcohol. A detrimental effect was found for leisure activities (sports and hobbies), occupational activities and for all activities combined ([@b0040]). We focused on the metabolic correlates, assessed through brain ^18^F-2-fluoro-2-deoxy-D-glucose-PET (^18^F-FDG-PET), of lifetime sport practice in a subset of the population-based ALS series recruited in Piedmont and Valle d'Aosta, Italy, in the context of the Euro-MOTOR Project.

2. Methods {#s0010}
==========

2.1. Partecipants recruitment {#s0015}
-----------------------------

The Euro-MOTOR Project was a multicentre, case-control, European study involving the Netherlands, Italy (Piedmont and Valle d'Aosta, Lombardy and Apulia regions) and Ireland, including incident cases diagnosed with definite, (laboratory-supported) probable or possible ALS according to the El Escorial revised criteria ([@b0045]) from February 2011 to February 2014 ([@b0050]). A structured questionnaire was administered to 1557 patients and 2922 controls in order to collect exposome data about PA (sports, hobbies, occupations), and many other factors, including traumas and pharmacological therapies. At the ALS Centre of Turin, Piedmont, Italy, 262 patients were enrolled in the Euro-MOTOR Project. Of these, 131 (50%) underwent brain ^18^F-FDG-PET at diagnosis, in the context of the research activity of our Centre about the metabolic correlates of neurodegeneration in ALS ([@b0055], [@b0060]), and were included in the present study. The other cases of the Euro-MOTOR sample did not undergo ^18^F-FDG-PET for the following reasons: denial, orthopnoea or difficulties reaching the PET Centre.

Forty subjects who were referred to the PET Centre for a suspected diagnosis of lung cancer in whom no oncologic disease was disclosed with ^18^F-FDG-PET/CT and who had a normal neurological assessment served as controls. Exclusion criteria were presence of major systemic illness, major vision disturbances, psychiatric illnesses, and diseases affecting brain functioning and metabolism.

2.2. Assessment of lifetime sport practice {#s0020}
------------------------------------------

Patients were interviewed through a structured questionnaire including many exposome aspects, as mentioned above, so limiting recall bias as much as possible. To quantify the lifetime exposure to PA, the Euro-MOTOR Project employed the Compendium of Physical Activities ([@b0065]). Such tool allows to estimate the metabolic consumption for each PA, calculated as the ratio to a standard resting condition (sitting quietly). The energy expenditure is expressed as MET (Metabolic Equivalent of Task): 1 MET corresponds to 1 Kcal/Kg body weight/h. The following formula was used to calculate the lifetime scores per participant, where *k* represents a specific PA:$$\underset{\text{k} = 1}{\overset{\text{n}}{\Sigma}}{(\text{MET}\,\text{scor}\text{e}_{\text{k}} \times \text{duration}\,\text{in}\,\text{year}\text{s}_{\text{k}} \times \text{hours}\,\text{per}\,\text{wee}\text{k}_{\text{k}})}$$

In the Euro-MOTOR Project such methodology allowed to quantify PA related to sport activities, hobbies and occupations with three distinct scores. All exposures were calculated up to 3 years before the enrolment in the survey, since over 95% of all participants of the Euro-MOTOR Study had a delay from disease onset to survey of\<3 years ([@b0050]). We considered only regular sport practice, i.e. physical exercise for at least 2 h per week, for at least three months. Patients were then classified into two groups: subjects who had never practiced sport regularly during their life (NO sport practice, i.e. N-group, for whom MET score related to sport was 0, n = 78), and those who had practiced sport regularly, regardless of the entity of the exposure (YES sport practice, i.e. Y-group, for whom MET score related to sports was \> 0, n = 53).

2.3. ^18^F-FDG-PET acquisition {#s0025}
------------------------------

^18^F-FDG-PET was performed according to published guidelines ([@b0070]). Briefly, subjects fasted at least six hours before the exam. Blood glucose was \< 7.2 mmol/l in all cases before the procedure. After a 20-minute rest, about 185 MBq of ^18^F-FDG were injected. The acquisition started 60 min after the injection. PET/CT scans were performed by a Discovery ST-E System (General Electric). Brain CT (thickness of 3.75 mm, 140 kVolt, 60--80 mAs) and PET scan (1 FOV of 30 transaxial centimetres) were sequentially acquired, being the former used for attenuation correction of PET data. Data were collected in 128 × 128 matrices with a reconstructed voxel of 2.34 × 2.34 × 2.00 mm.

2.4. Statistical analysis {#s0030}
-------------------------

Demographic and clinical characteristics and exposome data of the N-group and the Y-group were compared through Mann-Whitney and χ^2^ tests where applicable. Demographic characteristics of patient groups and healthy controls were compared through Mann-Whitney and χ^2^ tests where applicable. SPM8 implemented in Matlab 7.10.0 (MathWorks) was used for image normalization. A customized brain ^18^F-FDG-PET template, obtained from scans performed at the same centre, was utilized for spatial normalization. Intensity normalization was performed using the 0.8 default SPM value of grey matter threshold and images were subsequently smoothed with an 8-mm filter and submitted to statistical analysis. The ^18^F-FDG-PET data of the two groups were compared applying the *two-sample t-test* of SPM12, including age at PET, sex, site of onset (spinal/bulbar), presence/absence of *C9ORF72* expansion, ALS FRS-R (ALS Functional Rating Scale-Revised) total score at the time of PET, MET score related to hobbies and MET score related to occupational activities as covariates. The *height threshold* was set at p \< 0.01~uncorrected~, p \< 0.05~FWE-corrected~ at cluster level. Only clusters containing at least 100 contiguous voxels have been considered significant. Metabolic clusters showing a significant difference between the two groups were then used as *seed regions* in a *multiple regression analysis* for each group to identify cerebral regions whose metabolism was positively or negatively correlated with that of the *seed* clusters (i.e interregional correlation analysis, IRCA) ([@b0075]). In the IRCA the *height threshold* was set at p \< 0.005~uncorrected~; p \< 0.05~FWE-corrected~ at cluster level.

Then, each patient group (i.e. N-group and Y-group) was compared to healthy controls, setting the *height threshold* at p \< 0.05~FWE-corrected~; p \< 0.05~FWE-corrected~ at cluster level.

Brodmann areas (BAs) were identified at a 0--2 mm range from the Talairach coordinates of the SPM output isocentres corrected by Talairach Client (<http://www.talairach.org/index.html>).

Since the neuropsychological assessment was not available for 14 subjects out of 131, we performed a sensitivity analysis on the remaining 117 patients: we repeated the comparison between the N-group and the Y-group adding the cognitive status to the covariates mentioned above. The neuropsychological battery and the testing procedure have been previously described ([@b0080]). Based on the performance at the neuropsychological assessment, the cognitive status was classified as normal, frontotemporal dementia (FTD) and intermediate impairment (i.e. patients with cognitive and/or behavioural impairment not fulfilling criteria for full-blown FTD) according to published criteria ([@b0085]).

2.5. Ethical issues {#s0035}
-------------------

This work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and with Uniform Requirements for manuscripts submitted to Biomedical Journals. The study has been approved by the ethical committee "Comitato Etico Interaziendale Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino". Patients signed a written informed consent.

2.6. Data availability statement {#s0040}
--------------------------------

Data will be available upon request by interested researchers.

3. Results {#s0045}
==========

3.1. Demographic and clinical characteristics and exposome data {#s0050}
---------------------------------------------------------------

A descriptive summary statistics of covariates stratified by sport practice (N-group *versus* Y-group) is reported in [Table 1](#t0005){ref-type="table"}. We found a prevalence of males in the group who practiced sport (p = 0.001). The age at PET was lower in the Y-group as compared to the N-group (p \< 0.05). No significant difference was found for site of onset (bulbar/spinal), presence/absence of *C9ORF72* expansion, ALS FRS-R total score at the time of PET, MET score related to lifetime hobbies and MET score related to occupational activities.Table 1Descriptive summary statistics of covariates, stratified by sport activity (N-group *versus* Y-group).Sport activityTotalp\*N-groupY-groupSex*Female (%)*43 (55.1)14 (26.4)57 (43.5)**p = 0.001***Male (%)*35 (44.9)39 (73.6)74 (56.5)Age, median (IQR)67.5 (60.7--73.6)62.2 (51.8--70.6)67 (58.3--72.8)**p \< 0.05**Site of onset*Bulbar (%)*35 (44.9)16 (30.2)51 (38.9)p = 0.091*Spinal (%)*43 (55.1)37 (69.8)80 (61.1)*C9ORF72* expansion (%)11 (14.1)5 (9.4)16 (12.2)p = 0.423Total Occupation MET scores, median (IQR)3975 (2524--5775)3036 (2229--4860)3800 (2394--5670)p = 0.159Total Hobby MET scores, median (IQR)425 (148--1210)365 (60--1237)396 (96--1237)p = 0.449Total ALS FRS-R score, median (IQR)39 (36--43)41 (37--45)40 (36--44)p = 0.346Total78 (1 0 0)53 (1 0 0)131 (1 0 0)[^3][^4]

When considering only patients for whom the neuropsychological assessment was available (n = 117), the difference of cognitive status was not significant between N- and Y-group (p = 0.07; [Table 2](#t0010){ref-type="table"}). [Table 2](#t0010){ref-type="table"} reports no difference between the two groups in terms of previous general and head traumas and exposure to drugs related to sport practice (the list of drugs is reported in Inline [Supplementary Table 1](#s0095){ref-type="sec"}).Table 2Descriptive summary statistics of cognitive status, history of general and head traumas, and intake of sport-related drugs, stratified by sport activity (N-group *versus* Y-group).Sport activityTotalp\*N-groupY-groupCognitive status*Normal (%)*32 (47.1)32 (65.3)64 (54.7)p = 0.070*Intermediate (%)*21 (30.8)13 (26.5)34 (29.1)*FTD (%)*15 (22.1)4 (8.2)19 (16.2)*missing10414*General traumas*No (%)*21 (26.9)8 (15.1)29 (22.1)p = 0.109*Yes (%)*57 (73.1)45 (84.9)102 (77.9)Head traumas*No (%)*54 (69.2)36 (67.9)90 (68.7)p = 0.874*Yes (%)*24 (30.8)17 (32.1)41 (31.3)Sport-related drugs*No (%)*68 (87.2)47 (88.7)115 (87.8)p = 0.797*Yes (%)*10 (12.8)6 (11.3)16 (12.2)Total78 (1 0 0)53 (1 0 0)131 (1 0 0)[^5]

Sex and age at PET were included among covariates in the comparison between N-group and Y-group, while cognitive status was considered as covariate in the sensitivity analysis.

The control group (n = 40) showed median age at PET of 66.5 years (interquartile range 55--72), and male/female ratio of 2.64 (29/11). As compared to the control group, the N-group did not show any significant difference of age at PET (p = 0.172), while the male/female ratio was significantly lower in the N-group (p = 0.004). As compared to the control group, the Y-group did not show any significant difference of age at PET (p = 0.592) and male/female ratio (p = 0.907). Anyway, both age at PET and sex were included among covariates in the comparisons between each patient group and healthy controls.

3.2. ^18^F-FDG-PET {#s0060}
------------------

We did not find any region of relative hypometabolism in the N-group compared to the Y-group.

The N-group showed relative hypermetabolism compared to the Y-group in the cerebellum bilaterally ([Fig. 1](#f0005){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}).Fig. 1Glass brain rendering of the comparison between the N-group and the Y-group. The clusters showing a statistically significant, relative hypermetabolism in the N-group as compared to the Y-group are projected on brain surface. N-group: NO sport practice. Y-group: YES sport practice.Table 3Regions of relative hypermetabolism in the N-group as compared to the Y-group. N-group: NO sport practice. Y-group: YES sport practice.*P* (FWE*~corrected~*)Cluster extentZ-scoreTalairach coordinatesCluster site0.00117793.76−34−74−40Left CerebellumPosterior Lobe - Inferior Semi-Lunar Lobule3.67−10−50−26Left CerebellumAnterior Lobe - Dentate3.58−12−45−40Left CerebellumPosterior Lobe - Cerebellar Tonsil0.0259473.5926−72−40Right CerebellumPosterior Lobe - Inferior Semi-Lunar Lobule3.358−56−26Right CerebellumAnterior Lobe - Dentate

The sensitivity analysis showed substantially unchanged findings (data not shown).

The IRCA showed that in the N-group metabolism in such cerebellar cluster negatively correlated with metabolism in left medial and inferior frontal gyrus, insula, superior, transverse and middle temporal gyrus and in bilateral superior and middle frontal gyrus ([Fig. 2](#f0010){ref-type="fig"}A, [Table 4](#t0020){ref-type="table"}). In the Y-group the metabolism in this cerebellar cluster was negatively correlated with metabolism in smaller clusters including bilateral cingulate gyrus and right superior and middle frontal gyrus ([Fig. 2](#f0010){ref-type="fig"}B, [Table 5](#t0025){ref-type="table"}). The metabolism of the cerebellar cluster showed a positive correlation in both groups with the metabolism in corticospinal tracts, that was larger in the N-group ([Fig. 2](#f0010){ref-type="fig"}C) as compared to the Y-group ([Fig. 2](#f0010){ref-type="fig"}D).Fig. 2Results of the IRCA in the N-group, showing clusters of negative (A) and positive (C) correlation with metabolism of the cerebellar cluster of interest. Results of the IRCA in the Y-group, showing clusters of negative (B) and positive (D) correlation with metabolism of the cerebellar cluster of interest. N-group: NO sport practice. Y-group: YES sport practice.Table 4Results of the IRCA in the N-group: regions whose metabolism resulted negatively correlated with that of the cerebellar cluster of interest. IRCA: interregional correlation analysis. N-group: NO sport practice. BA: Brodmann Area.*P* (FWE*~corrected~*)Cluster extentZ-scoreTalairach CoordinatesCortical regionBA0.0009116.76−263341Left Middle Frontal Gyrus86.44−305021Left Superior Frontal Gyrus106.00−302249Left Superior Frontal Gyrus80.0002406.65305712Right Superior Frontal Gyrus100.00015686.53056−6Left Medial Frontal Gyrus105.98−24823Left Medial Frontal Gyrus95.8603137Left Medial Frontal Gyrus80.0005215.91282647Right Middle Frontal Gyrus85.62261356Right Middle Frontal Gyrus60.0002545.51−51−3418Left Insula135.00−59−1910Left Transverse Temporal Gyrus420.0002785.51−53−5921Left Superior Temporal Gyrus395.45−48−6129Left Middle Temporal Gyrus390.0002695.47−462624Left Middle Frontal Gyrus465.27−501329Left Inferior Frontal Gyrus90.0001135.41−4421−9Left Inferior Frontal Gyrus470.0001405.35−4802Left Superior Temporal Gyrus22Table 5Results of the IRCA in the Y-group: regions whose metabolism is negatively correlated with that of the cerebellar cluster of interest. IRCA: interregional correlation analysis. Y-group: YES sport practice. BA: Brodmann Area.*P* (FWE*~corrected~*)Cluster extentZ-scoreTalairach coordinatesCortical regionBA0.0143934.83264138Right Superior Frontal Gyrus83.73282647Right Middle Frontal Gyrus80.0008774.19−6240Left Cingulate Gyrus244.1921131Right Cingulate Gyrus24

The comparison between the N-group and healthy controls revealed a relative hypometabolism in the N-group in clusters including bilateral precentral gyrus, left middle frontal gyrus, left lingual gyrus, left inferior occipital gyrus, right angular gyrus, and bilateral cuneus (see Inline [Supplementary Figure 1](#s0095){ref-type="sec"} and Inline [Supplementary Table 2](#s0095){ref-type="sec"}). No areas of relative hypermetabolism in the N-group were found.

The comparison between the Y-group and healthy controls revealed a relative hypometabolism in the Y-group in the cuneus bilaterally (see Inline [Supplementary Figure 2](#s0095){ref-type="sec"} and Inline [Supplementary Table 3](#s0095){ref-type="sec"}). No areas of relative hypermetabolism in the Y-group were found.

4. Discussion {#s0065}
=============

In the present study we compared the brain metabolic pattern, as assessed through ^18^F-FDG-PET, of two groups of ALS patients, i.e. subjects who had never practiced sports regularly during their life (N-group), and subjects who practiced sport activities regularly, with different entity of exposure (Y-group). We found a significant, relative cerebellar hypermetabolism in the N-group as compared to the Y-group. The metabolism of the cerebellar cluster showed a negative correlation with metabolism of frontotemporal regions that resulted more significant and more widespread in the N-group as compared to the Y-group. Furthermore, the metabolism of the same cerebellar cluster showed a positive correlation with the metabolism of the corticospinal tracts in both groups, with a larger size of the cluster in the N-group. Such findings resulted independent of age at ^18^F-FDG-PET, sex, site of onset (bulbar/spinal), presence/absence of *C9ORF72* expansion, level of disability as assessed by ALS FRS-R total score, cognitive status and PA related to hobbies and occupations. Furthermore, when compared to healthy controls, the N-group showed more widespread cortical metabolic changes than the Y-group.

The finding of a cerebellar relative hypermetabolism has been already reported in ALS patients as compared to healthy controls ([@b0090]). Furthermore, a study evaluating the brain metabolic correlates at ^18^F-FDG-PET of the different degrees of cognitive impairment in ALS reported a decreasing gradient of frontal lobe metabolism from cognitively spared patients to subjects with frontotemporal dementia (FTD), while patients with mild cognitive deficits showed an intermediate metabolic behaviour. Strikingly, frontal lobe relative hypometabolism resulted associated with relative hypermetabolism in cerebellum, corticospinal tracts and midbrain, with increasing statistical significance and cluster size as the cognitive impairment increased ([@b0095]).

To interpret our finding of a cerebellar, relative hypermetabolism in the N-group, we employed the identified cerebellar cluster as *seed* region to evaluate which brain regions showed a positive or negative correlation of metabolism (i.e. interregional correlation analysis, IRCA). In the N-group cerebellar metabolism resulted negatively correlated with metabolism in bilateral frontal and left temporal regions. In the Y-group cerebellar metabolism was negatively correlated with bilateral cingulate cortex and right superior and middle frontal gyrus. Furthermore, we observed a positive correlation between the metabolism of the cerebellar cluster of interest and that of corticospinal tracts in both N- and Y-group, that resulted more extensive in the N-group. Indeed, relative hypermetabolism at ^18^F-FDG-PET of corticospinal tracts has been already reported in ALS and has been usually ascribed to gliosis due to motor axons degeneration ([@b0100]). Based on the larger size and the higher statistical significance of the frontotemporal clusters of negative correlation and the more extensive positive correlation with the corticospinal tracts detected in the N-group in the IRCA, we hypothesize that in the N-group the relative, cerebellar hypermetabolism is related to lower metabolic levels in frontotemporal regions and higher metabolic levels in corticospinal tracts, both possibly due to a more severe neurodegenerative process in areas already known to be involved in ALS ([@b0105], [@b0110]). The cerebellum is known to be involved in both motor and extra-motor function ([@b0115]). Its role in ALS has been investigated in different studies, with conflicting results. A study including MRI longitudinal assessment of ALS and PLS patients has shown significant white matter damage over time in different regions, including the cerebellum ([@b0120]). Otherwise, a recent multimodal MRI study has reported significantly decreased grey matter volume (GMV) in the left precentral gyrus, increased GMV in bilateral cerebellum, and decreased functional connectivity in the cerebellar anterior lobe in patients with ALS compared with healthy controls. The authors interpreted their findings as evidence of precentral degeneration and cerebellar compensation in ALS, suggesting that the white matter alterations mediate the relationship between the pathologies of the primary motor cortex and the cerebellum ([@b0125]). A possible explanation of such discrepancy has been hypothesized in a recent functional MRI study showing the coexistence of cerebellar circuits with decreased and increased connectivity, suggesting the concomitance of neurodegenerative and adaptive changes ([@b0130]).

Being the ALS FRS-R a score quantifying disability and functional impairment in ALS ([@b0135]), it can be considered as a measure of motor performance, albeit not accurate. So, we included it as a covariate in the analyses. Based on the results of the IRCA, we could hypothesize that N-patients can cope better with the neurodegenerative process due to ALS as compared to Y-patients, at the same level of disability as expressed by the ALS FRS-R score. Accordingly, when compared to healthy controls, the N-group showed more widespread metabolic changes than the Y-group in cortical regions known to be relatively hypometabolic in ALS patients as compared to healthy controls ([@b0105]), suggesting the presence of larger ALS-related brain metabolic changes in the N-group as compared to the Y-group, although the same level of motor disability.

Based on our results, we speculate that subjects who have never practiced sports are able to cope better with the neurodegenerative process. Since our patients underwent brain ^18^F-FDG-PET at diagnosis, the relative cerebellar hypermetabolism found in our study might represent an early adaptive mechanism to degeneration of frontotemporal regions and corticospinal tracts, probably destined to be overcome by neurodegeneration over time. If this resilience may be due to the preservation of compensatory mechanisms and/or brain reserve that can be exhausted by sport practice, can be subject to discussion. Indeed, this hypothesis could agree with the report of a lower age at ALS onset in professional athletes ([@b0030]). In this context, further aspects should be considered. Some studies suggest that subjects with relatively higher levels of cardiovascular ([@b0140]) and physical ([@b0145]) fitness show a higher risk of ALS. It is possible that PA is not a risk factor for ALS *per se*, but rather that a genetic profile promoting fitness also leads to increased ALS susceptibility ([@b0150], [@b0155]), or that PA anticipates the occurrence of the disease in genetically predisposed individuals ([@b0160]).

Nevertheless, this field needs further studies, overcoming the limitations of the present one. First, although the ALS FRS-R is a validated measure of disability caused by ALS, its total score does not provide an accurate estimation of motor performance. For such purpose the Walking Test or prolonged actigraphic registration may be possible tools. Second, the information resulting from ^18^F-FDG-PET, a valuable marker of neurodegeneration *in vivo* ([@b0165]), might be complemented by the different brain MRI techniques (voxel-based morphometry, diffusion tensor imaging, resting state imaging) and spinal cord MRI. Third, the use of MET to quantify PA does not take into account differences among persons in body mass, body fat percentage, age, cardiorespiratory fitness levels, and can be inaccurate in measuring activities performed in different environmental conditions [@b0065]. Anyway, albeit not free from limitations, the use of MET is suggested as a valuable tool to quantify lifetime exposure to PA ([@b0025]). Fourth, the classification of patients into two groups, i.e. N- and Y-group, does not consider the different entity of the exposure to sport practice. We tried to subdivide the Y-group in tertiles or into two groups according to the median value of MET scores related to sport practice (above median value and below median value). The comparisons between each subgroup of the Y-group and the N-group provided a trend towards results overlapping those obtained comparing the whole Y-group and the N- group, but not reaching statistical significance probably due to the reduced size of the subgroups. Furthermore, we performed a multiple regression analysis in the Y-group to evaluate the relationship between brain metabolism and MET scores related to sport practice, but we did not find any significant cluster (data not shown). The issue of the different levels of exposure to sport practice should be considered in future studies. In the study by Visser et al. [@b0040] a linear association between PA and ALS was reported: the more active a person has been, the higher the risk of developing ALS. Otherwise, other studies suggested that PA could have a different impact on ALS risk according to the level of exposure: a small amount could be protective and a higher level of activity detrimental [@b0160], [@b0170], [@b0175]. Finally, the age of the exposure to PA should be considered. Indeed, PA can modulate brain plasticity ([@b0180]), and it is well recognized that brain plasticity in response to environmental factors varies along the life course [@b0185], [@b0190]. As a consequence, PA might exert different effects according to the age of exposure.

On the other hand, the present study shows some strengths. To our knowledge, it is the first one employing neuroimaging to integrate epidemiological data in order to assess the impact of lifetime sport practice on the neurodegenerative process due to ALS. Second, the exposome data have been collected without stressing specific hypotheses about the risk of developing the disease, limiting recall bias as much as possible. Third, we were able to consider sport practice *per se*, eliminating the influence of PA due to hobbies and occupations. Fourth, we considered concomitant exposures (general traumas, head traumas, sport-related drugs) that can act as possible confounders, excluding their impact on our results. Actually, a potential impact of sport-related drugs cannot be completely ruled out, as the use of illicit drugs may have been under-reported by patients.

In conclusion, this is the first study about the brain metabolic correlates of lifetime sport practice in ALS and suggests that patients who never practiced sports regularly might cope better with the neurodegenerative process. Nevertheless, further studies are necessary to corroborate this hypothesis. They should stratify patients according to the age and the level of exposure to sport activity and employ more accurate tools to evaluate patients' motor performance and further imaging techniques to estimate the damage due to neurodegeneration at different levels.
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